CJC-1295 without DAC (Mod GRF 1-29)
Short GHRH pulse, no accumulation
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Also called Modified GRF 1-29. It is a short-acting copy of the body's own GH-releasing hormone. It signals the pituitary to release a brief pulse of growth hormone and is cleared quickly. It is the 'GHRH' half of the classic pairing with ipamorelin.
Quick reference
- Half-life
- About 30 minutes. Each dose creates a short pulse and is gone.
- Common range
- 100–300 mcg per injection, 1–3×/day, in fasting windows.
- Standard vial
- 10 mg + 3 mL of bacteriostatic water = 3,333 mcg/mL.
- Status
- Not approved by the FDA.
Typical Titration Pattern
| Phase | Window | Dose per injection | Notes |
|---|---|---|---|
| Initiation | Weeks 1-2 | 100 mcg, 1×/day | Pre-bed in a fasted window. Used to check tolerance. |
| Early escalation | Weeks 3-4 | 150 mcg, 1×/day | Increase by 50 mcg only if initiation is tolerated. |
| Therapeutic range | Weeks 5-8 | 200 mcg, 1×/day | Common maintenance level in community protocols. |
| Advanced range | Weeks 5–12+ | 200–300 mcg, 1–2x daily | Often split between morning fasted and pre-bed windows. |
| Upper community range | Protocol-dependent | Up to 300 mcg, up to 3x daily | Higher single doses tend to add side effects without bigger GH gains. |
Cycle Guidelines
| Approach | Length | Off period | Common use |
|---|---|---|---|
| Short cycle | 4-6 weeks | 2–4 weeks | Test tolerance and response. |
| Standard cycle | 8–12 weeks | 4-6 weeks | Most common maintenance pattern. |
| Pulsed week | 5 days on / 2 days off | Built into cycle | Used to keep pituitary receptors responsive. |
CJC-1295 No DAC Timeline & What to Monitor
| Window | What protocols typically look at |
|---|---|
| Per-dose (0–60 min) | Short flushing, mild headache, or warmth around the injection time. These fade with the compound. |
| First 1–2 weeks | Tolerance check at 100 mcg before stepping up. Sleep quality is the most commonly reported early marker. |
| Weeks 4-6 | Many planning frameworks treat this as a useful checkpoint for IGF-1 labs and to decide whether to raise dose or frequency. |
| Weeks 8–12 | Most cycles wrap up in this range, followed by 4–6 weeks off. |
CJC-1295 without DAC vs. with DAC vs. sermorelin vs. ipamorelin
| Property | CJC-1295 No DAC | CJC-1295 with DAC | Sermorelin | Ipamorelin |
|---|---|---|---|---|
| Class | GHRH analog | GHRH analog (binds albumin) | GHRH analog | GHRP (ghrelin mimetic) |
| Half-life | ~30 minutes | 6-8 days | 10–20 minutes | ~2 hours |
| Dosing frequency | 1–3x daily | 1–2x weekly | 1–2x daily | 1–3x daily |
| Common dose range | 100-300 mcg per injection | 1,000–2,000 mcg per week | 100–500 mcg per injection | 100-300 mcg per injection |
| GH release shape | Pulsatile, physiological | Sustained elevation | Pulsatile | Brief, selective pulse |
| FDA status | Not approved | Not approved | Previously approved; discontinued | Not approved |
| Standout feature | Cleanest pulsatile GHRH signal; easy titration | Convenient weekly dosing | Longest medical track record | GH pulse without cortisol or prolactin rise |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.